The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...
Low Vision Awareness Month Highlights Life-Changing Options for People with Vision Loss BLAINE, MN, UNITED STATES, ...
A tiny wireless implant is giving new hope to people blinded by advanced age-related macular degeneration. In a major ...
Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...
Investing.com -- Ocular Therapeutix (NASDAQ:OCUL) stock fell 25% Tuesday after the company reported top-line results from its Phase 3 SOL-1 superiority trial for Axpaxli in wet age-related macular ...
Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
Right now, Regeneron is trading for 17x forward earnings estimates, down from more than 25x in the second half of 2024. Considering this biotech's track record of growth and its solid pipeline, it's a ...
Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first lin ...
Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results